Karl Landsteiner
1868-1943 · Austriaco (posteriormente estadounidense) · Bioquímica
Inmunólogo austroamericano cuyo descubrimiento de los sistemas de grupos sanguíneos ABO y Rh estableció la individualidad química de la sangre humana, un avance paralelo a la era bioquímica en la que Jacoby y sus sucesores transformaron los extractos de sanguijuela en anticoagulantes caracterizados.
Perfil
- Años de vida
- 1868-1943
- Nacionalidad
- Austrian (later American)
- Época
- Principios del siglo XX
- Campo principal
- Bioquímica
Afiliaciones institucionales
- University of Vienna (Pathological Anatomy, 1898-1908)
- Wilhelminenspital, Vienna (Prosector)
- Rockefeller Institute for Medical Research, New York (1923-1943)
Contribuciones clave
- Discovered the ABO human blood group system in 1900-1901, identifying agglutinin reactions that established the chemical individuality of human blood and made safe transfusion possible.
- Co-discovered the Rhesus (Rh) blood group system in 1937 with Alexander Wiener, completing the immunohematological framework that underlies all modern transfusion medicine.
- Awarded the 1930 Nobel Prize in Physiology or Medicine for the discovery of human blood groups.
- Conducted pioneering work in immunochemistry and on the haptenic basis of antibody specificity, establishing the chemical foundations of serology.
- Worked at the Rockefeller Institute for Medical Research, New York, from 1923 until his death, bridging European and American biomedical traditions.
Importancia para la hirudoterapia
Karl Landsteiner is not a hirudotherapy researcher in any direct sense, and the American Society of Hirudotherapy includes him in the biographical registry as a representative of the broader biochemical revolution within which Karl Jacoby's hirudin standardization and Fritz Markwardt's hirudin purification became conceivable. Landsteiner's 1900-1901 discovery of the ABO blood group system was contemporaneous with Jacoby's 1902 industrialization of hirudin extraction, and both achievements illustrate the same epistemic shift: the move from clinical empiricism to a chemically characterized account of blood-related phenomena. Before this period, blood transfusion was unpredictable and often fatal, and leech therapy was justified by unverified humoral theory. After Landsteiner and his contemporaries, both transfusion medicine and anticoagulant pharmacology became reproducible chemical disciplines. The deeper connection between Landsteiner's work and hirudotherapy lies in the foundations of modern transfusion medicine that his blood group discoveries made possible. The clinical contexts in which leech therapy is now most clearly indicated — major reconstructive surgery, free flap salvage, digital replantation — all require sophisticated transfusion support, blood product management, and management of hemorrhagic complications. Without the ABO/Rh framework, the surgical complexity that justifies modern hirudotherapy would not exist. The leech, in this sense, is a downstream beneficiary of Landsteiner's immunohematology: he made the surgery possible that the leech now helps salvage. Landsteiner also represents, in the ASH registry, the broader pattern of early-twentieth-century immigration of European biomedical talent to the United States. Like many of his Austrian contemporaries, Landsteiner emigrated after the First World War and built the second half of his career at the Rockefeller Institute, contributing to the American tradition of biomedical research from which contemporary American hirudotherapy figures — Sawyer, Lineaweaver, Upton, Sherman, Siddall — also descend. He is the patron of the immunohematological framework within which modern blood-related interventions, including leech therapy, are clinically meaningful.
Publicaciones clave
- Über Agglutinationserscheinungen normalen menschlichen Blutes · Wiener klinische Wochenschrift (1901)
- An Agglutinable Factor in Human Blood Recognized by Immune Sera for Rhesus Blood (with A. S. Wiener) · Proceedings of the Society for Experimental Biology and Medicine (1940)
- The Specificity of Serological Reactions · Harvard University Press (1936)
Recursos externos
Investigación influenciada
Compuestos y áreas de investigación que se remontan a las contribuciones de esta figura:
Figuras relacionadas
John Berry Haycraft
1857-1922 · Británico (escocés)
Fisiólogo de Edimburgo que descubrió la hirudina en 1884, fundando la farmacología molecular moderna de la saliva de sanguijuela.
Karl Jacoby
1864-1926 · Alemán
German pharmacologist who in 1902 produced the first crude hirudin powder, bridging Haycraft's discovery to industrial-scale anticoagulant chemistry.
Marie Termier
1859-1930 · Francés
Médica francesa que en 1922 publicó uno de los primeros estudios clínicos formales de la terapia con sanguijuelas para la trombosis postquirúrgica, estableciendo la metodología clínica moderna en hirudoterapia.
Isabella P. Baskova
1936- · Ruso (soviético)
Bioquímica de la Universidad Estatal de Moscú que en 1986 descubrió la desestabilasa — la enzima de la sanguijuela que disuelve los coágulos de fibrina estabilizados incluso cuando la plasmina no puede.